Recce Pharmaceuticals (ASX:RCE) completed the dosing of 30 patients for a phase two trial investigating the use of the Recce 327 topical gel in patients with acute bacterial skin and skin structure infections, according to a Tuesday filing with the Australian bourse.

The open-label study aims to assess the safety and tolerability, plasma pharmacokinetics, and efficacy of the topical gel following daily application for seven to 14 days, the filing said.

Results from the study are anticipated within the first quarter, per the filing.

Shares of the pharmaceutical firm rose past 2% in recent Tuesday trade.